Wei Research Group
27
2025
Feb.
Our article entitled "Development and Preclinical Evaluation of [64Cu]Cu-NOTA- ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics" was published by The Journal of Nuclear Medicine.
5
2025
Feb.
Prof. Wei has been promoted to Associate Editor of Molecular Pharmaceutics. Congratulations!
9
2024
Sept.
Our review entitled "Molecular imaging of renal cell carcinomas: ready for prime time" was published by nature reviews urology.
14
2024
Nov.
Our article entitled "Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation" was published by The Journal of Nuclear Medicine.
7
2024
Nov.
Our article entitled "CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study" was published by The Journal of Nuclear Medicine.
9
2024
Sept.
Our article entitled "ImmunoPET imaging of EpCAM in solid tumours with nanobody tracers: a preclinical study" was published by European Journal of Medicine and Molecular Imaging.
3
2024
Sept.
Our review entitled "Trends in cancer imaging" was published by Trends in Cancer.
7
2024
Jul.
Our letter entitled "[18F]RCCB6 Immuno-Positron Emission Tomography/Computed Tomography for Postoperative Surveillance in Clear Cell Renal Cell Carcinoma: A Pilot Clinical Study" was published by European Urology.
In this prospective clinical study, we evaluated the safety and imaging efficacy of [18F]RCCB6. In terms of diagnosis, [18F]RCCB6 can detect lung, pancreas, and brain lesions in patients with ccRCC, compensating for the diagnostic shortcomings of conventional 18F-FDG imaging. In terms of post-treatment evaluation, [18F]RCCB6 effectively monitored metastatic foci such as lymph nodes, lung, and brain in postoperative ccRCC patients. Changes in [18F]RCCB6 uptake in some pulmonary metastatic lesions after targeted therapy suggest a role for [18F]RCCB6 in monitoring treatment response.
In conclusion, [18F]RCCB6 has an irreplaceable role in the comprehensive diagnosis of ccRCC, postoperative dynamic follow-up and monitoring of response to targeted therapies, which greatly improves the effectiveness of clinical diagnosis and treatment of ccRCC.
6
2024
May.
Our review entitled "Pathway to Approval of Innovative Radiopharmaceuticals in China" was published by The Journal of Nuclear Medicine.
5
2024
Apr.
Our research paper entitled "Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers" was published by Journal for ImmunoTherapy of Cancer.
Characterization of RW102 and ABDRW102.
[68Ga]Ga-NOTA-RW102 immunoPET imaging in subcutaneous tumor models.
[68Ga]Ga-NOTA-RW102 immuno-positron emission tomography imaging of an adult patient with squamous lung cancer with 70% PD-L1 expression.
Characterization of RW102 and ABDRW102.
2
2024
Apr.
Our research paper entitled "ImmunoPET imaging of Trop2 in patients with solid tumours" was published by EMBO Mol Med.
Recent research highlights Trop2 as an adverse prognostic biomarker in multiple solid tumors, correlating its high expression with reduced survival and increased tumor aggressiveness, while targeting Trop2 may impede tumor growth and metastasis.
We have developed two nanobody radiopharmaceuticals targeting human Trop2 with one of the tracers ([68Ga]Ga-NOTA-T4) showing favourable pharmacokinetics and promising diagnostic capabilities in both preclinical studies and a pilot clinical trial.
Characteristics of two nanobodies (T4 and T5) targeting human Trop2.
[68Ga]Ga-NOTA-T4 and [68Ga]Ga-NOTA-T5 immunoPET imaging in T3M-4 models.
[18F]-FDG and [68Ga]Ga-NOTA-T4 PET/CT imaging in a patient with small-cell lung cancer.
Characteristics of two nanobodies (T4 and T5) targeting human Trop2.
This work introduces a groundbreaking clinical-grade Trop2 probe in the field of nuclear medicine, marking a significant breakthrough. This innovative tracer holds promise in altering cancer diagnosis and treatment outcomes. With its precision and sensitivity, the Trop2 probe opens new avenues in oncological imaging, enabling earlier detection and more targeted therapies. Its arrival foreshadows a shift towards personalized medicine, equipping clinicians with potent tools to combat cancer effectively.
14
2024
Mar.
Our research paper entitled "ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study" was published by EJNMMI.
CD70 emerges as a promising biomarker for RCC, exhibiting high expression levels within tumors.
Leveraging immunoPET imaging, our research team has developed sdAb tracers targeting CD70, such as [18F]RCCB6, demonstrating potential for precise visualization and monitoring of RCC. Preclinical studies indicate specific uptake of these tracers by CD70-positive tumors. Clinical trial suggests the safety and efficacy of this approach in detecting widespread metastases, including brain metastases, markedly outperforming traditional PET/CT scans. Additionally, our team has prepared tracers like [18F]RB6 by removing His tags from sdAbs, potentially aiding in the detection of primary ccRCC.
Future endeavors of our research team aim to optimize sdAb engineering and assess tracer efficacy in various tumor using advanced imaging techniques.
25
2023
Oct.
In collaboration with Prof. Haojun Chen, we have developed several new integrated probes for FAP theranostics.
19
2023
Oct.
In the short paper, we discussed the essentials of theranostics focusing on antibody theranostics. Together with the opinions from Wolfgang A. Weber et al, we can enrich the contents of theranostics and use theranostic approaches to improve clinical practice.
25
2023
Sept.
The research paper entitled "Site-Specific Modification of Single Domain Antibodies by Enzyme-Immobilized Magnetic Beads" in collaboration with prof. Changfeng Wu‘s group was published by Bioconjugate Chemistry.
Working with Prof. Wu's group, we have devised a new strategy for efficient labelling of single domain antibodies by immobilized-enzymes.
8
2023
Aug.
Our research paper entitled "ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers" was published by EJNMMI.
24
2023
On July 24, 2023, Dr. Wei became a member of the Editorial Board of the "EJNMMI"
Jul.
an internationainterdisciplinary journal that publishes papers in the field of radiopharmaceutical imaging andtherapy, molecular imaging and advanced imaging analyses.
5
2023
Jul.
Our research paper entitled "ImmunoPET Imaging of CD47 with VHH-Derived Tracers in Pancreatic Cancers" was published by molecular pharmaceutics.
早餐做法
為您提供
5
2023
Jul.
The American Journal of Nuclear Medicine and Molecular Imaging now has an impact factor of 2.500
10-11
2023
Mar.
Prof. Dawei Jiang from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and prof. Haojun Chen from the Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University visited our group.
10
2023
Feb.
Our review entitled "Antibody theranostics in precision medicine" was published by Med.
1
2023
Feb.
Our research paper entitled "Development and characterization of nanobody-derived CD47 theranostic pairs in solid tumors" was published by Research.
27
2022
Dec.
Our research paper entitled "Development and comparison of 68Ga/18F/64Cu-labeled nanobody tracers probing Claudin18.2" was published by Molecular Therapy Oncolytics.
